These data strongly suggest that it would be promising in aggressive or recurrent meningioma to target either alone or in combination, the Pi3K-AKT-mTOR pathway with the Pi3K inhibitor alpelisib and the MAP kinase pathway with the MEK inhibitor trametinib. This evidence concerns the gene MTOR and meningioma.